Impact of Evolocumab in Cardiac Transplant Patients With CAV

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.
Epistemonikos ID: 4726a30f1ca718ebe600c6cb8c558caeeff62745
First added on: May 22, 2024